CAGR For OTC Switch Forecast At 5%, But Without Statins, Asthma Treatments

OTC switch product sales are estimated to grow at a compounded annual growth rate of 5% by 2019, with opportunities likely emerging in bladder control for women and sleep aids, according to Kline Market Research. But asthma drugs and statins are not likely to debut OTC soon, notes analyst Laura Mahecha.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

More from North America